Wire · opportunities
Revance and Teoxane announce the US FDA approval of RHA Redensity Eye for undereye ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
Revance and Teoxane received FDA approval for RHA Redensity Eye, a hyaluronic acid filler designed to treat moderate to severe undereye hollows in adults. This treatment offers up to 12 months of natural-looking results with a strong safety profile, addressing an important aesthetic area especially relevant for patients experiencing fat loss due to GLP-1 therapies.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You face a new opportunity to offer a clinically proven, FDA-approved filler tailored for undereye hollows with lasting effect and strong patient-reported outcomes. This clears a path to expand services for aesthetics patients sensitive to fat loss regions, pushing competitors to match this precision formulation.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics